REGENXBIO Inc — Balance Sheet (NASDAQ:RGNX) | MetaTrader

Open full chart

Financials

Overview 明細書 Statistics Dividends

Quarterly Annual

Total assets 708.16 M1.11 B833.27 M573.97 M465.99 M Total liabilities 330.41 M349.61 M317.07 M262.23 M206.34 M Total equity 377.75 M764.3 M516.2 M311.74 M259.65 M Total liabilities & shareholders' equities 708.16 M1.11 B833.27 M573.97 M465.99 M Total debt ————— Net debt —————

ニュース

FDA長官の発言を受けてスティフェルがuniQure株についてコメント

Stifel comments on uniQure shares after FDA commissioner remarks

Uniqure Plummets As FDA's Marty Makary Disparages Rejected Rare Disease Drug

Regenxbio (RGNX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Is the SPDR S&P Biotech ETF (XBI) a ‘Strong Buy’ Right Now? - TipRanks.com

REGENXBIO: Cautiously Bullish After FDA Setbacks (NASDAQ:RGNX)

Regenxbio stock price target lowered to $32 at H.C. Wainwright after FDA rejection

REGENXBIOの希少疾患治療法への道はFDAの拒否によって曇りました

Intel, Wells Fargo among market cap stock movers on Tuesday

Netflix and Oracle among market cap stock movers on Tuesday

Regenxbio stock price target lowered by Goldman Sachs on RGX-121 setback

時間外取引の注目銘柄：オン・セミコンダクター、Credo、Upwork、Regenxbioなど